BUSINESS INSIGHTS

A BLOCKCHAIN TO ENSURE COUNTERFEIT FREE PHARMACEUTICAL SUPPLY CHAIN

February 5, 2022

A BLOCKCHAIN
Essential medicine access is one of the main objectives of healthcare systems in and pharmaceutical supply chains
ensure that the right amount of medicine, with acceptable quality, will reach the customers in need

Spotlight

Myoderm

For nearly 30 years, Myoderm has been a specialist in global clinical trial supply, with deep expertise in sourcing, management, and labeling of commercial drugs and supplies. Our ingenuity, strategic thinking, and obsession with providing the most efficient, effective, and seamless supply solutions is why top pharmaceutical companies, biotech companies, CROs, and clinical trial packagers around the world rely on Myoderm for their supply needs. With headquarters in Europe and North America, and an extensive global network of manufacturers and suppliers, we pride ourselves on our proven ability to locate branded, generic and OTC products in all therapeutic classes and dosage forms – including the most hard-to-find medications. And, we are fully licensed for the storage and distribution of prescription medications including controlled drugs.

OTHER WHITEPAPERS
news image

Research and Development in the Pharmaceutical Industry

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

Read More
news image

THE PHARMACEUTICAL INDUSTRY AND GLOBAL HEALTH

whitePaper | January 31, 2022

COVID-19 is an infectious disease caused by a newly discovered coronavirus, which was first identified in December 2019.

Read More
news image

The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

whitePaper | April 16, 2020

Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing unexpected cost increases for payers and consumers, and spurring an investigation by the United States Congress. High generic drug prices have had an adverse effect on almost everyone in the pharmaceutical supply chain. Consumers face higher co-pays and prices and health plans are dealing with higher drug spend. Physicians are finding the need to prescribe alternative drug therapies while dealing with angry patients.

Read More
news image

A Vision for the Global Generic and Biosimilar Medicines Industry

whitePaper | May 22, 2021

One of the key roles of the generic and biosimilar medicines industry is specifically to promote the widest possible access to affordable medicines with high quality, safety, and efficacy for patients globally by introducing competition into the markets. Despite the many hurdles, the generic medicines companies have clearly lived up to the challenges posed by the pandemic as it is an industry that is quick to adapt and agile in manufacturing scale-up. During the outbreak of COVID-19, this industry was providing most of the medicines needed in Intensive Care Units to ventilate critically ill COVID patients. It is also providing most of the quality medicines dispensed around the world, especially for increasingly prevalent chronic diseases and is therefore a strong contributor to health outcomes globally.

Read More
news image

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

Read More
news image

Understanding Net Pharmaceutical Expenditure Dynamics in Europe

whitePaper | April 12, 2022

The level of pharmaceutical expenditure is closely watched and often commented upon, but the composition of that expenditure and its dynamics are not as well understood.

Read More

Spotlight

Myoderm

For nearly 30 years, Myoderm has been a specialist in global clinical trial supply, with deep expertise in sourcing, management, and labeling of commercial drugs and supplies. Our ingenuity, strategic thinking, and obsession with providing the most efficient, effective, and seamless supply solutions is why top pharmaceutical companies, biotech companies, CROs, and clinical trial packagers around the world rely on Myoderm for their supply needs. With headquarters in Europe and North America, and an extensive global network of manufacturers and suppliers, we pride ourselves on our proven ability to locate branded, generic and OTC products in all therapeutic classes and dosage forms – including the most hard-to-find medications. And, we are fully licensed for the storage and distribution of prescription medications including controlled drugs.

Events